We are live on ! Find out more
PBAXU

Phoenix Biotech Acquisition Corp. Unit
PBAXU

Delisted

PBAXU was delisted on the 7th of February, 2024.

Back to rankings

28 hedge funds and large institutions have $32.6M invested in Phoenix Biotech Acquisition Corp. Unit in 2022 Q1 according to their latest regulatory filings, with 2 funds opening new positions, 1 increasing their positions, 9 reducing their positions, and 11 closing their positions.

New
Increased
Maintained
Reduced
Closed

24% less funds holding

Funds holding: 37 → 28 (-9)

50% less capital invested

Capital invested by funds: $65.5M → $32.6M (-$32.9M)

82% less first-time investments, than exits

New positions opened: 2 | Existing positions closed: 11

89% less repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 9

Holders
28
Holders Change
-9
Holders Change %
-24.32%
% of All Funds
0.44%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
2
Increased
1
Reduced
9
Closed
11
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
WAM
Wolverine Asset Management
Illinois
+$17.6K
2
CS
Clear Street
New York
+$8.62K

Top Sellers

Rank Fund Capital Flow
1
PC
Periscope Capital
Ontario, Canada
-$6.05M
2
HIM
HGC Investment Management
Ontario, Canada
-$5.04M
3
LA
Linden Advisors
New York
-$5.04M
4
MI
MMCAP International
Cayman Islands
-$5.04M
5
CCM
Context Capital Management
California
-$4.04M

PBAXU Hedge Fund Activity: Q1 2022 in Review

28 of the 6,360 institutional investors tracked by Wall St. Rank reported a position in Phoenix Biotech Acquisition Corp. Unit (PBAXU) for Q1 2022, worth a combined $32.6M — down 50% from $65.5M a quarter earlier.

Sellers outnumbered buyers: 11 funds closed out of PBAXU and 2 opened new positions — a net loss of 9 holders — while 9 trimmed existing stakes and 1 added.

The largest buyer was Wolverine Asset Management, adding an estimated $17.6K. The largest seller was Periscope Capital, exiting entirely with an estimated $6.05M sold.

  • 28 institutional investors held Phoenix Biotech Acquisition Corp. Unit (PBAXU) as of Q1 2022, down from 37 in Q4 2021.
  • Funds reported $32.6M of Phoenix Biotech Acquisition Corp. Unit stock for Q1 2022, down 50% quarter-over-quarter.
  • 2 funds opened new Phoenix Biotech Acquisition Corp. Unit positions in Q1 2022 and 11 closed out, a net change of -9 holders.
  • The largest Phoenix Biotech Acquisition Corp. Unit buyer in Q1 2022 was Wolverine Asset Management, an estimated $17.6K added.
  • The largest Phoenix Biotech Acquisition Corp. Unit seller in Q1 2022 was Periscope Capital, an estimated $6.05M sold.

Based on aggregated 13F filings for Q1 2022.